Resolution of Staphylococcus aureus biofilm infection using vaccination and antibiotic treatment

Infection and Immunity

Volumn 79, Issue 4, 2011, Pages 1797-1803

  Brady, Rebecca A ^a,d   O'May, Graeme A ^a   Leid, Jeff G ^b   Prior, Megan L ^a   Costerton, J William ^c   Shirtliff, Mark E ^a  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b NORTHERN ARIZONA UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSAMINIDASE; PROTEIN SA0037; PROTEIN SA0486; PROTEIN SA0688; RECOMBINANT PROTEIN; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL VIRULENCE; BIOFILM; CHRONIC OSTEOMYELITIS; CONTROLLED STUDY; FEMALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; RABBIT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; VACCINATION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; BIOFILMS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROSCOPY, CONFOCAL; OSTEOMYELITIS; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VACCINATION; VANCOMYCIN;

EID: 79953300499     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00451-10     Document Type: Article

References (41)

1. Anetzberger, C., T. Pirch, and K. Jung. 2009. Heterogeneity in quorum sensing-regulated bioluminescence of Vibrio harveyi. Mol. Microbiol. 73:267-277.
2. Beenken, K. E., et al. 2004. Global gene expression in Staphylococcus aureus biofilms. J. Bacteriol. 186:4665-4684.
3. Biswas, R., et al. 2006. Activity of the major staphylococcal autolysin Atl. FEMS Microbiol. Lett. 259:260-268.
4. Brady, R. A., J. G. Leid, A. K. Camper, J. W. Costerton, and M. E. Shirtliff. 2006. Identification of Staphylococcus aureus proteins recognized by the antibody-mediated immune response to a biofilm infection. Infect. Immun. 74:3415-3426.
5. Brady, R. A., J. G. Leid, J. Kofonow, J. W. Costerton, and M. E. Shirtliff. 2007. Immunoglobulins to surface-associated biofilm immunogens provide a novel means of visualization of methicillin-resistant Staphylococcus aureus biofilms. Appl. Environ. Microbiol. 73:6612-6619.
6. Brouillette, E., et al. 2002. DNA immunization against the clumping factor A (ClfA) of Staphylococcus aureus. Vaccine 20:2348-2357.
7. Brown, M. R., D. G. Allison, and P. Gilbert. 1988. Resistance of bacterial biofilms to antibiotics: a growth-rate related effect? J. Antimicrob. Chemother. 22:777-780.
8. Brown, M. R., and P. Gilbert. 1993. Sensitivity of biofilms to antimicrobial agents. J. Appl. Bacteriol. 74(Suppl.):87S-97S.
9. Donlan, R. M., and J. W. Costerton. 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15:167-193.
10. Fattom, A. I., G. Horwith, S. Fuller, M. Propst, and R. Naso. 2004. Development of StaphVAX, a polysaccharide conjugate vaccine against Staphylococcus aureus infection: from the lab bench to phase III clinical trials. Vaccine 22:880-887.
11. Fitzpatrick, F., H. Humphreys, and J. P. O'Gara. 2005. Evidence for icaADBC-independent biofilm development mechanism in methicillin-resistant Staphylococcus aureus clinical isolates. J. Clin. Microbiol. 43:1973-1976.
12. Fontana, C., L. Cellini, and B. Dainelli. 1993. Twelve aberrant strains of Staphylococcus aureus subsp. aureus from clinical specimens. J. Clin. Microbiol. 31:2105-2109.
13. Foster, S. J. 1995. Molecular characterization and functional analysis of the major autolysin of Staphylococcus aureus 8325/4. J. Bacteriol. 177:5723-5725.
14. Horan, T. C., et al. 1993. Nosocomial infections in surgical patients in the United States, January 1986-June 1992. National Nosocomial Infections Surveillance (NNIS) Syst. Infect. Control Hosp. Epidemiol. 14:73-80.
15. Josefsson, E., O. Hartford, L. O'Brien, J. M. Patti, and T. Foster. 2001. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J. Infect. Dis. 184:1572-1580.
16. Klevens, R. M., et al. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771.
17. Kretsinger, K., et al. 2006. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm. Rep. 55:1-37.
18. Kuklin, N. A., et al. 2006. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect. Immun. 74:2215-2223.
19. Kyaw, M. H., et al. 2006. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. 354:1455-1463.
20. Mader, J. T., and K. Adams. 1989. Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillinresistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob. Agents Chemother. 33:689-692.
21. Mader, J. T., and M. E. Shirtliff. 1999. The rabbit model of bacterial osteomyelitis of the tibia. Academic Press, Ltd., London, England.
22. Maira-Litran, T., et al. 2002. Immunochemical properties of the staphylococcal poly-N-acetylglucosamine surface polysaccharide. Infect. Immun. 70: 4433-4440.
23. Maira-Litran, T., A. Kropec, D. A. Goldmann, and G. B. Pier. 2005. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated staphylococcal poly-N-acetyl-β-(1-6)-glucosamine. Infect. Immun. 73:6752-6762.
24. McKenney, D., et al. 2000. Vaccine potential of poly-1-6 β-D-N-succinylglucosamine, an immunoprotective surface polysaccharide of Staphylococcus aureus and Staphylococcus epidermidis. J. Biotechnol. 83:37-44.
25. McKenney, D., et al. 1999. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 284:1523-1527.
26. Ni, E. D., et al. 1998. Clumping factor B (ClfB), a new surface-located fibrinogen-binding adhesin of Staphylococcus aureus. Mol. Microbiol. 30: 245-257.
27. Nilsdotter-Augustinsson, A., A. Koskela, L. Ohman, and B. Soderquist. 2007. Characterization of coagulase-negative staphylococci isolated from patients with infected hip prostheses: use of phenotypic and genotypic analyses, including tests for the presence of the ica operon. Eur. J. Clin. Microbiol. Infect. Dis. 26:255-265.
28. O'Neill, E., et al. 2007. Association between methicillin susceptibility and biofilm regulation in Staphylococcus aureus isolates from device-related infections. J. Clin. Microbiol. 45:1379-1388.
29. Resch, A., et al. 2006. Comparative proteome analysis of Staphylococcus aureus biofilm and planktonic cells and correlation with transcriptome profiling. Proteomics 6:1867-1877.
30. Richardson, A. R., S. J. Libby, and F. C. Fang. 2008. A nitric oxide-inducible lactate dehydrogenase enables Staphylococcus aureus to resist innate immunity. Science 319:1672-1676.
31. Rohde, H., et al. 2007. Polysaccharide intercellular adhesin or protein factors in biofilm accumulation of Staphylococcus epidermidis and Staphylococcus aureus isolated from prosthetic hip and knee joint infections. Biomaterials 28:1711-1720.
32. Ryding, U., J. I. Flock, M. Flock, B. Soderquist, and B. Christensson. 1997. Expression of collagen-binding protein and types 5 and 8 capsular polysaccharide in clinical isolates of Staphylococcus aureus. J. Infect. Dis. 176:1096-1099.
33. Schaffer, A. C., et al. 2006. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect. Immun. 74:2145-2153.
34. Shinefield, H., et al. 2002. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 346:491-496.
35. Shirtliff, M. E., and J. T. Mader. 2000. Osteomyelitis: clinical features and molecular aspects of persistence. ASM Press, Washington, DC.
36. Stewart, P. S., and M. J. Franklin. 2008. Physiological heterogeneity in biofilms. Nat. Rev. Microbiol. 6:199-210.
37. Stranger-Jones, Y. K., T. Bae, and O. Schneewind. 2006. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc. Natl. Acad. Sci. U. S. A. 103:16942-16947.
38. Takahashi, J., et al. 2002. Molecular characterization of an atl-null mutant of Staphylococcus aureus. Microbiol. Immunol. 46:601-612.
39. Wang, R., et al. 2007. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat. Med. 13:1510-1514.
40. Watson, D. L. 1987. Serological response of sheep to live and killed Staphylococcus aureus vaccines. Vaccine 5:275-278.
41. Zhou, H., Z. Y. Xiong, H. P. Li, Y. L. Zheng, and Y. Q. Jiang. 2006. An immunogenicity study of a newly fusion protein Cna-FnBP vaccinated against Staphylococcus aureus infections in a mice model. Vaccine 24:4830-4837.